Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer

被引:9
|
作者
Ren, Yifan [1 ]
Song, Jialong [1 ]
Li, Xinyi [1 ]
Luo, Na [1 ]
机构
[1] Nankai Univ, Sch Med, Dept Histol, Tianjin 300071, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer therapy; metastatic triple-negative breast cancer; anticancer drugs; immunotherapy; immune checkpoint blockade therapy; PD-1; PD-L1; clinical trails; CHECKPOINT BLOCKADE; ANTITUMOR IMMUNITY; 1ST-LINE TREATMENT; PLUS CHEMOTHERAPY; DOUBLE-BLIND; OPEN-LABEL; T-CELLS; ATEZOLIZUMAB; PEMBROLIZUMAB; THERAPY;
D O I
10.3390/ijms23168878
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metastatic triple-negative breast cancer (mTNBC), a highly aggressive and malignant tumor, currently lacks an effective treatment. There has been some progress in the treatment of mTNBC with programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) immunotherapy in recent years. The combination of PD-1/PD-L1 inhibitors with other therapies is a noteworthy treatment strategy. Immunotherapy in combination with chemotherapy or small-molecule inhibitors still faces many challenges. Additionally, there are some new immunotherapy targets in development. We aimed to further evaluate the effectiveness and usefulness of immunotherapy for treating mTNBC and to propose new immunotherapy strategies. This review explains the rationale and results of existing clinical trials evaluating PD-1/PD-L1 inhibitors alone or in combination for the treatment of mTNBC. For patients with aggressive tumors and poor health, PD-1/PD-L1 inhibitors, either alone or in combination with other modalities, have proven to be effective. However, more research is needed to explore more effective immunotherapy regimens that will lead to new breakthroughs in the treatment of mTNBC.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma
    Tang, Quanqing
    Li, Shihao
    Huang, Gaozhen
    Liu, Hongwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 119
  • [32] PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
    Jiang, Yongshuai
    Chen, Ming
    Nie, Hong
    Yuan, Yuanyang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (05) : 1111 - 1122
  • [33] MHC Class I Loss in Triple-negative Breast Cancer A Potential Barrier to PD-1/PD-L1 Checkpoint Inhibitors
    Dusenbery, Anna C.
    Maniaci, Joseph L.
    Hillerson, Natalie D.
    Dill, Erik A.
    Bullock, Timothy N.
    Mills, Anne M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (05) : 701 - 707
  • [34] Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer
    Li, Guangxin
    Hu, Jiajia
    Cho, Christina
    Cui, Junwei
    Li, Ao
    Ren, Pengwei
    Zhou, Jichun
    Wei, Wei
    Zhang, Tianxiang
    Liu, Xiaoling
    Liu, Weiru
    CELLULAR SIGNALLING, 2023, 109
  • [35] Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
    Wang, Luyao
    Yang, Zongxing
    Guo, Fucheng
    Chen, Yurong
    Wei, Jiarui
    Dai, Xiangpeng
    Zhang, Xiaoling
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [36] Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer
    Mavratzas, Athanasios
    Seitz, Julia
    Smetanay, Katharina
    Schneeweiss, Andreas
    Jaeger, Dirk
    Fremd, Carlo
    FUTURE ONCOLOGY, 2020, 16 (03) : 4439 - 4453
  • [37] Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer
    Li, Yijin
    Vennapusa, Bharathi
    Chang, Ching-Wei
    Tran, David
    Nakamura, Rin
    Sumiyoshi, Teiko
    Hegde, Priti
    Molinero, Luciana
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (04) : 258 - 264
  • [38] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
    Barclay, Jonathan
    Creswell, Joanne
    Leon, Juan
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
  • [39] PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy
    Salmaninejad, Arash
    Valilou, Saeed Farajzadeh
    Shabgah, Arezoo Gowhari
    Aslani, Saeed
    Alimardani, Malihe
    Pasdar, Alireza
    Sahebkar, Amirhossein
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (10) : 16824 - 16837
  • [40] Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects
    Ahmed, Rida Fatima
    Jameel, Farwah
    Irfan, Muhammad
    CRITICAL REVIEWS IN IMMUNOLOGY, 2019, 39 (03) : 211 - 221